ISDA: 3S35

Deposition Date 2011-05-17

Release Date 2011-08-24

Last Version Date 2024-11-20

Entry Detail

PDB ID:

3S35

Keywords:

IMMUNE SYSTEM/Transferase

Title:

Structural basis for the function of two anti-VEGF receptor antibodies

Biological Source:

Source Organism:

Mus musculus, Homo sapiens (Taxon ID: 10090, 9606)
Homo sapiens (Taxon ID: 9606)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.20 Å

R-Value Free:

0.25

R-Value Work:

0.20

R-Value Observed:

0.20

Space Group:

C 2 2 21

Download Validation Report

Macromolecular Entities

Polymer Type:polypeptide(L)
Molecule:6.64 Fab heavy chain
Chain IDs:A (auth: H)
Chain Length:217
Number of Molecules:1
Biological Source:Mus musculus, Homo sapiens

Polymer Type:polypeptide(L)
Molecule:6.64 Fab light chain
Chain IDs:B (auth: L)
Chain Length:217
Number of Molecules:1
Biological Source:Mus musculus, Homo sapiens

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Vascular endothelial growth factor receptor 2
Gene (Uniprot):KDR
Chain IDs:C (auth: X)
Chain Length:122
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P35968 Pfam ID:PF00047 EC:2.7.10.1

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
ASN	C	ASN	GLYCOSYLATION SITE

Ligand Molecules

NAG

Primary Citation

The Structural Basis for the Function of Two Anti-VEGF Receptor 2 Antibodies.

Franklin, M.C, Navarro, E.C, Wang, Y, Patel, S, Singh, P, Zhang, Y, Persaud, K, Bari, A, Griffith, H, Shen, L, Balderes, P, Kussie, P.Show

Structure 19 1097 1107 (2011)

PMID: 21827946 DOI: 10.1016/j.str.2011.01.019

Abstact

The anti-VEGF receptor 2 antibody IMC-1121B is a promising antiangiogenic drug being tested for treatment of breast and gastric cancer. We have determined the structure of the 1121B Fab fragment in complex with domain 3 of VEGFR2, as well as the structure of a different neutralizing anti-VEGFR2 antibody, 6.64, also in complex with VEGFR2 domain 3. The two Fab fragments bind at opposite ends of VEGFR2 domain 3; 1121B directly blocks VEGF binding, whereas 6.64 may prevent receptor dimerization by perturbing the domain 3:domain 4 interface. Mutagenesis reveals that residues essential for VEGF, 1121B, and 6.64 binding are nonoverlapping among the three contact patches.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form